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Abstract: Methylmalonic acidemia is an inborn metabolic disease of propionate catabolism, biochemically
characterized by accumulation of methylmalonic acid (MMA) to millimolar concentrations in tissues
and body fluids. However, MMA’s role in the pathophysiology of the disorder and its status as a
“toxic intermediate” is unclear, despite evidence for its ability to compromise antioxidant defenses
and induce mitochondrial dysfunction. Coenzyme Q10 (CoQ10) is a prominent electron carrier in
the mitochondrial respiratory chain (MRC) and a lipid-soluble antioxidant which has been reported
to be deficient in patient-derived fibroblasts and renal tissue from an animal model of the disease.
However, at present, it is uncertain which factors are responsible for inducing this CoQ10 deficiency
or the effect of this deficit in CoQ10 status on mitochondrial function. Therefore, in this study,
we investigated the potential of MMA, the principal metabolite that accumulates in methylmalonic
acidemia, to induce a cellular CoQ10 deficiency. In view of the severe neurological presentation of
patients with this condition, human neuroblastoma SH-SY5Y cells were used as a neuronal cell model
for this investigation. Following treatment with pathological concentrations of MMA (>0.5 mM),
we found a significant (p = 0.0087) ~75% reduction in neuronal cell CoQ10 status together with a
significant (p = 0.0099) decrease in MRC complex II–III activity at higher concentrations (>2 mM).
The deficits in neuronal CoQ10 status and MRC complex II–III activity were associated with a loss of
cell viability. However, no significant impairment of mitochondrial membrane potential (∆Ψm) was
detectable. These findings indicate the potential of pathological concentrations of MMA to induce a
neuronal cell CoQ10 deficiency with an associated loss of MRC complex II–III activity. However, in the
absence of an impairment of ∆Ψm, the contribution this potential deficit in cellular CoQ10 status
makes towards the disease pathophysiology methylmalonic acidemia has yet to be fully elucidated.
Keywords: coenzyme Q10; mitochondrial respiratory chain; methylmalonic acidemia; mitochondrial
dysfunction; mitochondrial membrane potential
1. Introduction
Methylmalonic acidemia is an organic acidemia which although clinically difficult to manage can
show improvement as the result of treatment. This condition can result from either a deficiency in
l-methylmalonyl-CoA mutase (MCM; MIM 251000) activity, a deficit in 5-deoxyadenosyl cobalamin
(the active form of vitamin B12) synthesis or availability (MIM 251110), and in rare cases it can be
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caused by a deficiency in the activity of methylmalonyl-CoA epimerase (MCE; MEM 251120) [1].
Biochemically, methylmalonic acidemia is characterized by the accumulation of methylmalonic acid
(MMA) in tissues and body fluids, such as blood plasma or serum and cerebrospinal fluid (CSF),
although the majority of biochemical studies use urine to determine MMA levels in patients [2]. The two
major disease phenotypes are isolated methylmalonic acidemia and combined methylmalonic acidemia
with homocystinuria. The isolated variant of this condition can be caused by either a complete deficiency
(enzymatic subtype mut0) or a partial deficiency (subtype mut-) in MCM activity, or can result from
defects in the transport or synthesis of adenosylcobalamin (cblA and cblB). As a result of these deficiencies,
the catabolic pathway of branched chain amino acids is impaired in methylmalonic acidemia [1,3].
Methylmalonic acidemia presents in infancy with episodes of metabolic acidosis, although this
condition can also present in adulthood [1,3]. Damage to the central nervous system which can present as
developmental delay and coma, together with chronic kidney disease are amongst the severe consequences
of this disease, although this condition can also be fatal in some cases [1,3]. However, disease severity
and individual symptoms can vary, ranging from a benign clinical presentation to a fatal neonatal
syndrome [4]. A comprehensive overview of the clinical presentations of methylmalonic acidemia is
outlined by Baumgartner et al. (2014) [4]. Despite recent management guidelines for the treatment
of methylmalonic acidemia this disorder is associated with significant morbidity and mortality [4].
Athough some patients with methylmalonic acidemia may respond to cobalamin therapy, in severe
cases of the disease the transplantation of affected organs such as the liver and kidney may be considered
in order to overcome local enzyme deficiencies [5]. However, neurological deterioration post transplant
is common, and patients remain susceptible to a “metabolic stroke”, with CSF MMA levels remaining
significantly high post liver transplantation, despite reduction in serum levels [6,7]. The commonly
used therapy for the treatment of patients with methylmalonic acidemia involves the dietary restriction
of natural proteins to limit the intake of isoleucine, valine, methionine, and threonine together with
the provision of a high energy diet, although this can result in amino acid deficiencies and has been
associated with poor growth [8,9].
MMA has been previously reported to induce neuron apoptosis and oxidative stress (OS) in
different cell culture systems [10–12]. Furthermore, the mitochondrial toxicity of MMA has been
examined in both in vitro and in vivo systems [13]. MMA has also been reported to induce an increase in
lipid and protein peroxidation as well as to decrease the activity of the antioxidant enzyme, superoxide
dismutase in rat brain and kidney tissue, the pro-oxidant effect of MMA was found to be potentiated
by the induction of renal failure [11,14]. The metabolites 2-methylcitrate (2-MCA) and malonate (MA)
have also been reported to accumulate in methylmalonic acidemia together with MMA and have been
implicated in neuronal death and MRC impairment, although their mechanism of actions have yet to
be fully elucidated [3,15].
A number of studies have demonstrated evidence of both single and multiple mitochondrial
respiratory chain (MRC) enzyme deficiencies in patients with methylmalonic acidemia [16–18]. An in vitro
study using rat cerebra cortex reported that MRC complex II–III (NADH: cytochrome c reductase;
EC: 1.6.5.3 + EC: 1.10.2.2) and complex II–III (succinate: cytochrome c reductase; EC: 1.3.5.1 + EC: 1.10.2.2)
activities were significantly reduced following treatment with 1, 2.5 and 5 mM MMA [19]. Although the
activity of MRC complex I (NADH:ubiquinone reductase; EC: 1.6.5.3) was also found to be decreased
following MMA exposure, the activities of individual MRC II (succinate dehydrogenase: ubiquinone
reductase; EC: 1.3.5.1) and complex III (ubiquinol: cytochrome c reductase; EC: 1.10.2.2) were not
affected [19]. Therefore, in view of the dependence of MRC complex II–III activity upon endogenous
coenzyme Q10 (CoQ10), the decrease in the activity of this enzyme following MMA exposure may have
resulted from a deficit in CoQ10 status induced by this metabolite [20]. However, this possibility was
not further investigated in the study by Brusque et al. (2002) [19].
CoQ10 serves as an electron carrier within the MRC as well as functioning as an important
lipid-soluble antioxidant [21]. In its role as an electron carrier within the MRC, CoQ10 allows a
continuous passage of electron in the chain enabling the process of oxidative phosphorylation to occur
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with the concomitant production of ATP [21]. The antioxidant function of CoQ10 is attributed to its
fully reduced ubiquinol form. In addition to its electron carrier and antioxidant functions, CoQ10 has
also been reported to have anti-inflammatory properties and be involvement in DNA replication and
repair [22,23].
Haas et al. (2009) [24] revealed evidence of a deficit in fibroblast CoQ10 status in patients with
methylmalonic acidemia who demonstrated no residual MCM activity [24]. A further study reported a
decreased in the level of renal CoQ10 in a MUT-knockout mouse model of methylmalonic acidemia.
However, the level of coenzyme Q9 (CoQ9) which is the predominant ubiquinone species in mouse [20]
was comparable to control levels [25]. At present, only two studies have reported evidence of an
association between a CoQ10 deficiency and methylmalonic acidemia, and the factors responsible for
eliciting this deficit in cellular CoQ10 status have yet to be investigated. In view of the possibility that
the CoQ10 deficiency associated methylmalonic acidemia may be caused by one of the metabolites that
accumulate in this condition, a possible candidate to consider would be MMA since this is the principal
compound that accumulates to mM concentrations in the body fluids and brain tissue of patients
with methylmalonic acidemia during acute metabolic crisis [19,26]. Therefore, the aims of this study
were to investigate the potential of MMA to induce a cellular CoQ10 deficiency as well as to provide
further evidence supporting an association between this condition and a deficit in endogenous CoQ10
status and mitochondrial dysfunction. In view of the severe neurological presentation of patients with
methylmalonic acidemia [13], human neuroblastoma SH-SY5Y cells were chosen as the appropriate
cell line for this investigation.
2. Results
2.1. The Effect of MMA Treatment on Neuronal CoQ10 Status and MRC Complex II–III Activity
To assess the effect of MMA treatment on the neuronal MMA status, and to confirm that this
metabolite was taken up by the SH-SY5Y cells, the intracellular concentration of MMA was analysed
by liquid chromatography–tandem mass spectrometry (LC-MS) following 7 days of culture with
exogenous MMA (2 and 5 mM). Intracellular concentrations of MMA of 3.01 ± 1.14 nmol/mg and
5.28 ± 0.25 nmol/mg (mean ± SD; n = 3) were determined following 7 days of incubation with 2 mM
and 5 mM, respectively. These results indicated that, interestingly, control cells were found have an
endogenous MMA concentration of 0.64 ± 0.16 nmol/mg (mean ± SD; n = 3).
Following incubation with MMA, neuronal CoQ10 status was found to be significantly decreased
(** p = 0.0087, Figure 1a) compared to control levels for all treatment groups (0.5, 1, 2 and 5 mM MMA).
Interestingly, although 0.5 mM MMA induced an approximate 75% decrease in cellular CoQ10 status,
the treatment of the SH-SY5Y cells with higher concentrations of MMA (1, 2, 5 mM; Figure 1a) did not
result in a further deficit in cellular CoQ10 status which was decreased to a similar level following
all treatments.
The effect of this deficit in neuronal CoQ10 status was then investigated on MRC activity by
determining the activity of MRC complex II–III, a linked enzyme system whose activity is dependent
upon endogenous CoQ10 status [20]. MMA treatment was found to decrease complex II–III activity,
although this only reached significance at 2 mM (* p = 0.0099, Figure 1b). The effect of MMA treatment
upon the activity of the mitochondrial marker enzyme, citrate synthase (CS, EC. 2.3.3.8) [27] was
also undertaken to ensure that the diminution in neuronal CoQ10 status did not simply reflect a
loss in mitochondrial enrichment since approximately 50% of cellular CoQ10 is located within this
organelle [28]. No significant changes were found between the concentration range (ns, p = 0.081,
Figure 1c).
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Figure 1. Effect of MMA treatment (0.5, 1, 2 and 5 mM) on neuronal cell CoQ10 status, the cellular 
CoQ10 concentration is expressed as pmol/mg of protein (a). Effect of MMA treatment (0.5, 1, 2 and 5 
mM) on neuronal cell MRC complex II–III activity (b). Effect of MMA treatment (0.5, 1, 2 and 5 mM) 
on neuronal cell CS activity (c). Error bars represent the mean ± SEM of n = 4 observations (a) and n = 
3 (b,c). Statistical analysis was carried out using the Kruskal–Wallis test with Dunn’s multiple 
comparisons. ** p = 0.0087, * p = 0.0099. 
2.2. The Effect MMA Treatment on SH-SY5Y Viability and Mitochondrial Membrane Potential 
The effect of the MMA-induced CoQ10 deficiency and loss of MRC complex II–III activity was 
assessed on SH-SY5Y neuronal cell viability by use of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay. Following treatment with MMA a progressive in the reduction 
in MTT reaching significance (* p = 0.010, Figure 2a) which induced a 54.7% loss in cell viability 
compared to control levels. Using phase-contrast microscopy, no significant changes in neurite 
length, cellular phenotype (S/N) or cell rounding were observed between MMA-treated and control 
cells (Figure 2b), indicating that the loss of viability post treatment with MMA may have resulted 
from as yet unknown causes. No significant difference was found between the protein concentrations 
of the control and 5 mM MMA-treated cell samples, 4.07 ± 0.22 mg/mL and 4.22 ± 0.40, respectively 
(mean ± SEM, n = 5). 
The effect of the MMA-induced CoQ10 deficiency and loss of MRC complex II–III activity was 
also assessed on SH-SY5Y neuronal cell mitochondrial membrane potential (ΔΨm) via flow 
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2.2. The Effect MMA Treatment on SH-SY5Y Viability and Mitochondrial Membrane Potential
The effect of the MMA-induced CoQ10 deficiency and loss of MRC complex II–III activity was
assessed on SH-SY5Y neuronal cell viability by use of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) assay. Following treatment with MMA a progressive in the reduction in
MTT reaching significance (* p = 0.010, Figure 2a) which induced a 54.7% loss in cell viability
compared to control levels. Using phase-contrast microscopy, no significant changes in neurite length,
cellular phenotype (S/N) or cell rounding were observed between MMA-treated and control cells
(Figure 2b), indicating that the loss of viability post treatment with MMA may have resulted from as yet
unknown causes. No significant difference was found between the protein concentrations of the control and
5 mM MMA-treated cell samples, 4.07 ± 0.22 mg/mL and 4.22 ± 0.40, respectively (mean ± SEM, n = 5).
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micrograph of SH-SY5Y morphology following treatment with 5 mM MMA, S and N phenotypes are 
retained; (c) ΔΨm determination of SH-SY5Y cells as determined by JC-1 flourescence probe 
following treatment with MMA (0.5, 1, 2 and 5 mM). Error bars represent the mean ± SEM, n = 6. 
Statistical analysis was carried out using the Kruskal–Wallis test with Dunn’s multiple comparisons. 
* p = 0.0099. 
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patients. In view of the severe neurological symptoms associated with methylmalonic acidemia [4] 
and the fact that neurons may be exposed to CSF MMA levels as high as 2.5–5 mM during crises 
[19,26], we used this study to investigate whether MMA at these concentrations may have the 
potential to induce a neuronal cell CoQ10 deficiency. The 75% decrease in cellular CoQ10 status 
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a MMA-induced CoQ10 deficiency and suggests the possibility that a deficit in CoQ10 status may be a 
contributory factor to the neurological dysfunction associated with this disorder. However, further 
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The effect of the MMA-induced CoQ10 deficiency and loss of MRC complex II–III activity was
also assessed on SH-SY5Y neuronal cell mitochondrial membrane potential (∆Ψm) via flow cytometry
using the Ψm-specific probe, JC-1. However, MMA treatment was found to have no significant effect
on neuronal cell ∆Ψm (ns, p = 0.284, Figure 2b) compared to the control.
3. Discussion
To our knowledge, this is the first study to report the ability of MMA to induce a deficit in cellular
CoQ10 status. This indicates the possibility that elevated levels of MMA, previously reported in
methylmalonic acidemia [2] may have the potential to induce an endogenous CoQ10 deficiency in
patients. In view of the severe neurological symptoms associated with methylmalonic acidemia [4] and
the fact that neurons may be exposed to CSF MMA levels as high as 2.5–5 mM during crises [19,26],
we used this study to investigate whether MMA at these concentrations may have the potential to
induce a neuronal cell CoQ10 deficiency. The 75% decrease in cellular CoQ10 status following exposure
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of the neuronal cells to 0.5 mM MMA indicates the susceptibility of these cells to a MMA-induced
CoQ10 deficiency and suggests the possibility that a deficit in CoQ10 status may be a contributory
factor to the neurological dysfunction associated with this disorder. However, further studies will be
required before this can be confirmed or refuted. In view of the dependence of MRC complex II–III
activity upon endogenous CoQ10 status [20], the effect of the MMA-induced CoQ10 deficiency was
assessed on the activity of this enzyme system. However, although the activity of complex II–III was
decreased after neuronal exposure to all concentrations of MMA, a significant loss of activity was
only observed following treatment with 2 mM MMA. The reasons for this are uncertain in view of the
comparable levels of residual CoQ10 present in the neuronal cells following treatment with the different
concentrations of MMA. However, the possibility arises that in addition to a deficit in CoQ10 status,
the loss of complex II–III activity may also be the result of MMA-induced inhibition of either complex
II or III activity, which may only be induced at higher concentrations of the acid. However, a study by
Brusque et al. (2002) [19] also reported the ability of MMA to inhibit the activity of MRC complex II–III
activity in rat cerebral cortex homogenates in the absence of a deficit in either individual complex II
or III activity. Unfortunately, no assessment of CoQ10 was undertaken in the study by Brusque et al.
(2002) [19]. However, the ability of MMA to act as competitive inhibitor of MRC complex II activity
was reported. However, complex II activity was only inhibited by MMA (1, 2.5 and 5 mM) when 1 mM
of succinate was used as the substrate concentration for the assay [19]. A concentration of 20 mM was
used to assess MRC complex II–III activity in the present study and therefore, it is unlikely that the
loss of enzyme activity may be attributable to MMA-induced complex II inhibition, although this has
yet to be confirmed or refuted and the possibility arises that the loss of complex II–III activity may be
attributable to other factors associated with MMA treatment such as OS or direct enzyme inhibition
which may only occur at the higher concentrations of the acid [10–12,14].
Interestingly, although MMA was found to induce a 75% decrease in neuronal cell CoQ10 status
together with a 61% decrease in MRC complex II–III activity (2 mM MMA), there appeared to be no
apparent loss of ∆Ψm as assessed by the JC-1 cationic fluorescent dye assay. A possible explanation
for this result is that CoQ10 and complex II–III may have to be inhibited beyond 75% and 61%,
respectively of control levels before the ∆Ψm becomes impaired. Indeed, it has been reported that the
activity of MRC complex III, a component of complex II–III has to be inhibited by approximately 80% of
its original activity before oxidative phosphorylation becomes compromised in synaptic mitochondria
isolated from rat brain [29].
Two previous studies have reported evidence of an association between methylmalonic acidemia
and a deficit in CoQ10 status, one in patient fibrobasts [24] and the other in a mouse model of the
disease [25]. However, in these studies the factors responsible for inducing the loss of CoQ10 status
were not investigated, and the present study is the first to indicate that MMA may be capable of
causing a diminution in the status of this isoprenoid. However, the mechanism by which this occurs
is at present uncertain. The comparable levels of CS activity, the mitochondrial marker enzyme [27]
between the control and MMA-treated cells suggests that the decrease in CoQ10 status does not reflect
a loss in mitochondrial enrichment of the neurons. The possibility arises that MMA may be able to
directly inhibit one or more of the enzymes involved in CoQ10 biosynthesis. The reported ability of
MMA to inhibit MRC complex I activity together with complex II–III [19], the latter being confirmed in
the present study, may also be an explanation for the decrease in CoQ10 status of the neuronal cells.
The loss of MRC complex I and linked II–III activity following MMA treatment would be expected to
reduce electron flow in the MRC and therefore, the requirement for the electron carrier, CoQ10 whose
synthesis may then be suppressed as suggested in the study by Yudero et al. (2016) resulting in a
decrease in the cellular level of this isoprenoid [30]. Furthermore, in view of the reports of OS in
methylmalonic acidemia [31] together with its association with MMA treatment [10–12], the decrease
in neuronal CoQ10 status observed in the present study may also result from either increased oxidative
catabolism of the molecule or reactive oxygen species induced inhibition of the enzymes involved
in CoQ10 biosynthesis [32]. The possibility also arises that MMA may sequester CoaSH resulting in
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a decrease in cellular acetyl-CoA availability which is required by the mevalonate pathway for the
synthesis of CoQ10 [21]. A decrease in cellular acetyl-CoA availability has been previously suggested
by Yubero et al., 2014 [33] as one of the possible mechanisms to account for an association between a
CoQ10 and a glucose transporter deficiency. Further studies will be required to assess evidence for this
putative mechanism of CoQ10 deficiency in methylmalonic acidemia.
Commensurate with the deficit in CoQ10 status and MRC complex II–III activity, a significant
decrease in the reduction in MTT (p = 0.010) by the SH-SY5Y cells following exposure to 5 mM MMA
was observed. Since the MTT assay assesses cellular metabolic activity as an indicator of cell viability,
proliferation and cytotoxicity [34] from the results of the present study we cannot be certain as yet to
the causes of the loss of reduction in MTT and further studies will be required to confirm or refute
whether this reflects a loss in cell viability or cellular proliferation. However, the similar levels of
CS activity, the mitochondrial marker enzyme [35] and cell protein following MMA exposure may
indicate that differences in cell proliferation may not be solely responsible for the results of the MTT
assay. Although the deficit in CoQ10 status and complex II–III activity appear to have contributed to
the loss in cell viability, other factors should also be considered that may explain why a significant
loss in cell viability was only observed following exposure to 5 mM MMA. However, at present, these
factors have yet to be elucidated. Further, it should be noted that following addition of 5 mM MMA
to the cell culture media there was a decrease in pH from 7.49 to 7.02, and although this did not
appear to have a direct effect on the enzyme and MTT assays used in the present study it is at present
uncertain whether this had a detrimental effect on MRC complex II–III activity and/or cell viability and
this requires further investigation. The reported inhibitory effect of MMA on MRC activity should
also be a consideration [19]. However, the maintenance of the ∆Ψm following exposure to MMA
suggests that impaired oxidative phosphorylation may not have been a contributory factor. Importantly,
MMA treatment in animal and cell studies has been reported to induce an increase in lipid and protein
peroxidation as well as to decrease the activity of the antioxidant enzyme, superoxide dismutase and
the level of cellular antioxidant, glutathione [10–12,14,31]. Therefore, a MMA-induced increase in
OS may have also contributed to the loss of neuronal cell viability, although this was not investigated in
the present study. The MMA-induced decrease in cellular CoQ10 status would also be expected to have
contributed to cellular OS in view of the important antioxidant function of this molecule [21].
It is important to stress that this study was conducted in SH-SY5Y human neuroblastoma cells,
which, although possess many of the functional and biochemical properties of early sympathetic
neurons, are heavily dependent upon glycolysis for ATP generation in contrast to primary neurons
which rely on oxidative metabolism for energy generation [36,37]. Therefore, although SH-SY5Y cells
are commonly used as a human neuronal cell model [36], further studies will be required before it can
be confirmed or refuted whether MMA has the potential to induce a CoQ10 deficiency in methylmalonic
academia patients. However, taking this caveat into the consideration, this study highlights the
vulverability of neuronal cells to MMA-induced CoQ10 deficiency, with 0.5 mM MMA being suffient to
induce an approximate 75% decrease in the level of this isoprenoid. This is especially pertinent since it
has been reported that the level of MMA may be as high as 2.5–5 mM in the blood and cerebrospinal fluid
(CSF) of methylmalonic acidemia patients during crisis, possibly being even higher in neuronal cells [26].
Currently, there is a paucity of information in the literature on the use of CoQ10 in the treatment
of methylmalonic acidemia. However, CoQ10 treatment in conjunction with vitamin E has been
reported to improve visual acuity in a 15-year-old patient with methylmalonic acidemia and optic
neuropathy [38]. Furthermore, a significant improvement in glomerular filtration rate was reported in
a mouse model of the condition following co-treatment of vitamin E and CoQ10 [25].
In conclusion, the results of this study have indicated the susceptibility of SH-SY5Y human
neuroblastoma cells to MMA-induced CoQ10 deficiency which is also associated with a loss in
MRC complex II–III activity (Figure 3). Although this study was undertaken in SH-SYSY human
neuroblastoma cells, a widely used model for human neuronal cells, it remains to be determined
whether the findings of this study are translatable to neurons in vivo. Therefore, the possibility arises
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that the cellular CoQ10 status of methylmalonic acidemia patients exposed to concentrations of MMA
≥ 0.5 mM may be decreased compared to unaffected individuals, although this needs to be confirmed
or refuted. The assessment of the endogenous CoQ10 status of these patients may prove informative.
However, further studies are required to determine whether this potential deficit in neuronal CoQ10
status contributes to the disease pathophysiology of methylmalonic acidemia.
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4.1. Cell Culture 
The SH-SY5Y neuroblastoma cell line was purchased from the European Collection of Cell 
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4. Materials and Methods
4.1. Cell Culture
The SH-SY5Y neuroblastoma cell line was purchased from the European Collection of Cell
Cultures (Health Protection Agency, Salisbury, UK). This is thrice cloned cell line with a neuroblast-like
morphology. The SK-N-SH cell line, from which these cells were originally cloned, has demonstrated
various neurotransmitter activities: dopaminergic, acetylcholinergic and adenosinergic [39].
SH-SY5Y cells (human bone marrow neuroblastoma; ATCC CRL-2266) with epithelial and
neuroblast-like phenotypes were cultured in Dulbecco’s Eagles Modified Medium (DMEM) (Sigma Aldrich),
supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicilin Streptomycin (P/S) at 37 ◦C.
Cell densities modified based upon incubation periods.
The concentrations of MMA used in the present study are based on those reported in the blood
and CSF of methylmalonic acidemia patients which have been reported to be ≥2.5 mmol/L during
acute metabolic crisis, [19,26]. In view of the fact that the half life of cerebral ubiquinone species
(coenzyme Q9 and CoQ10) have been reported to be 90 h (3.75 days), and to ensure that the majority
of the endogenous CoQ10 synthesized prior to MMA treatment had been degraded, a time course of
7 days was selected for this study [40]. For these experiments stock solutions of MMA were prepared
by dissolving MMA in Milli-Q water.
At 70–90% confluence, cells were harvested, washing twice with phosphate buffer saline (PBS)
followed by the addition of trypsin (3 mL). Cells were seeded in plastic 96-well plates at a density
of 20,000 cells/well or T75 flasks at a density of 150,000 cells/mL prior to treatments with MMA.
MMA treatment was carried out in DMEM at concentrations of 0.5, 1, 2 and 5 mM and SH-SY5Y
cells were treated with MMA for 7 days without a media change during the 7 day incubation period.
As the MMA was dissolved in Milli-Q water, control cells were treated with the vehicle Milli-Q water
(50 µL). The pH of the cell culture media was determined following addition of MMA to assess whether
there was any change in the pH of the environment to which the cells were exposed during culture.
Following the inclusion of MMA in the cell culture media the pH changed from 7.49 to 7.76,7.68,7.49
and 7.02 after the addition of 0.5, 1, 2 and 5 mM MMA, respectively.
4.2. High-Performance Liquid Chromatography (HPLC)
Total cellular CoQ10 status was quantified using a HPLC UV detection method as previously
described by Duncan et al. 2005 [41]. CoQ10 was extracted from the cell samples according to the
method of Boitier et al. (1998) [42] using a solvent of hexane: ethanol (5:2, v/v). Cells samples together
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with the internal standard (di-propoxy CoQ10) were vigorous mixed in eppendorf tubes with the solvent
and subjected to centrifugation (5 min × 5000× g at 4 ◦C) and the upper hexane layer was retained for
analysis. The lower aqueous layer was extracted two more times with solvent and the resulting upper
hexane layers were combined and evaporated under nitrogen gas. During the extraction procedure all
cellular ubiquinol should be oxidised to CoQ10. The sample was then re-suspensed in HPLC-grade
ethanol before being injected onto the HPLC. separation was achieved using a reverse phase C18
column (150 × 4.6, HPLC Technology, Welwyn Garden City, UK), using a mobile phase composed of
methanol/ethanol/perchloric acid (700:300:1.2) at a flow rate of 0.7 mL/min. CoQ10 was detected at
275 nm using a PG-975-50 UV/VIS detector (Jasco, Essex, UK). Cellular CoQ10 content was estimated
by comparison with a standard solution of CoQ10.The inter and intra assay coefficient of variation
(CV) for this assay using the cell samples were 2.6% (331 nmol/L; n = 5) and 3.5% (371 nmol/L; n = 5),
respectively. Upon injection of 2 and 5 mM MMA into the HPLC system, no peaks were detected on
the HPLC chromatogram at 275 nm, indicating that this metabolite does not co-elute with or influence
the accurate determination of CoQ10. All quantification in pmol/mg was expressed relative to total
protein content via the Lowry Assay.
4.3. Spectrophotometric Enzyme Assays
Enzymatic determinations were undertaken at 30 ◦C using a Uvikon XL spectrophotometer
(Northstar, Leeds, UK).
The specific activities of the MRC enzymes were determined according to previously described methods:
Complex II/III (succinate dehydrogenase: cytochrome c reductase; EC. 1.3.5.1 + 1.10.2.2) was
measured by the antimycin A sensitive reduction in cytochrome c at 550 nm according to the method
developed by King [43]. Antimycin A is a specific inhibitor of complex III activity, and therefore in the
assay, the enzymatic rate pre antimycin A addition is subtracted from the activity post antimycin A
addition to provide a complex II–III-specific enzyme activity [43].
CS activity was determined by the liberation of free CoA with DTNB (5,5′ dithio-bis (2-nitrobenzoic
acid) which forms a stable conjugate that can measured at 412 nm according to the method of Shepherd
and Garland [35]. Complex II–III activities were expressed as a ratio to CS activity to correct for the
mitochondrial enrichment of the samples [44].
In the absence of SH-SY5Y cells 5 mM MMA was not found to affect the complex II–III or CS
enzyme assays.
4.4. MTT Assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was used to
assess to assesses the cellular metabolic activity (an indicator of cell viability, proliferation and
cytotoxicity of the SH-SY5Y human neuroblastoma cells. This colormetric assay is based on the
ability of the mitochondrial enzyme NADPH-dependant cellular oxidoreductase enzymes to reduce
MTT to its purple coloured insoluble formazan which absorbs at 590 nm which is proportional to
the NADPH-dependent reductase cellular activity, and accordingly, proportional to the number of
proliferating and viable cells [34]. Post addition of trypan blue solution, dye excluding cells were
counted using a haemocytometer. Cells were then plated and treated with MMA as previously
described. MTT solution (20 µL) was added to each well of the 96 well plate post a 7 day incubation
with the MMA. After a 3–4 h incubation with MTT at 37 ◦C, the formazan product was solubilized
using 100 µL of DMSO and the absorbance of each well was read at 570 nm on a CLARIOstar® Plus.
In the absence of SH-SY5Y cells, 5 mM MMA was not found to affect the MTT assay.
4.5. Flow Cytometry
JC-1 (5,5,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi-dazoylcarbocyanine iodide) is a cationic
fluorescent dye that accumulates in energized mitochondria. JC-1 assay measures the mitochondrial
membrane potential, in that the fluorescent intensity of the dye indicates an increase or decrease in
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mitochondria membrane potential. After 7 day incubation with MMA, neuroblastoma cells were
washed with 20 µL of PBS and stained with JC-1 (1:2000 dilution), cells were gently mixed and left
to incubate at 37 ◦C, 5% CO2 for 30 min. After incubation, cells were washed with PBS (20 µL),
and trypsinized before being analysed on a flow cytometer using 488 nm excitation [45].
4.6. Protein Determination
Protein concentrations of the SH-SY5Y cell samples were determined by the method of Lowry
and colleagues (1951) [46] using BSA as a standard.
4.7. Determination of Intracellular MMA Concentrations
The cellular levels of MMA were determined in SH-SY5Y cells by stable-isotope dilution and
liquid chromatography–tandem mass spectrometry according to the method of Blom et al. (2007) [47].
The cell samples were frozen and thawed 4 times in liquid nitrogen followed by vigorous vortex mixing.
The samples were then diluted 1 in 200 with Milli-Q water. The diluted samples were mixed with a
solution containing a stable isotopically labelled MMA standard and then subjected to ultrafiltration.
After removal of water, hydrochloric acid (HCL, 1 mM) and butanol were added to the sample to
esterify the residue. Solvent and HCl were removed and the residue was re-dissolved in mobile
phase prior to analysis by liquid chromatography–tandem mass spectrometry. MMA was quantified
according to known standards.
4.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism (Version 8.4.1. 460 for macOS). A p value
of < 0.05 was considered to be statistically significant. Before performing analyses, distributions of
data were checked for normality with the Shapiro–Wilk test. Measurement data were expressed as the
mean ± standard error of the mean (SEM). For all data deemed non-parametric, the Kruskal–Wallis
test with Dunn’s multiple comparison was used to evaluate statistical significance between control and
MMA-treated cells. In all cases, p < 0.05 was considered significant.
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